Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11th,...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Compan...
WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a business update. “We made considerable progress during the quarter despite the sustained headwinds of the COVID-19 pandemic, as we continued to advance our Phase 3 registration clinical trials addressing Acine...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020. The details of the poster presentations include:“Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical...
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15th, the Cantor 2020 Virtual Global Healthcare Conference on September 17th, and ...
Proceeds to support the ongoing ATTACK Phase 3 registration clinical trialWALTHAM, Mass., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitive agreement to sell securities in a private placement with Innoviva, Inc. (Nasdaq: INVA), a company with a portfolio of royalties, and another health...